Andrew Smith
Dentist Murray, UT Doctor of Dentistry
NPI 1134263478 CMS profile 1022081
6040 Fashion Blvd Ste 100, Ste 100, Murray, UT 84107
General payments
$1,348
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$589,075
Through program year 2025, Andrew Smith of Murray, UT is reported in the CMS Open Payments database as having received $1,348 across 18 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $589,075 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 85th percentile of Dentist profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $115 | 3 | |
| 2023 | General | $620 | 5 | |
| 2021 | General | $310 | 1 | |
| 2020 | General | $90 | 1 | |
| 2019 | General | $214 | 8 |
Beside peers
- Andrew Smith
- Dentist median
- Middle half of Dentist
- National median
In program year 2025, general payments to Andrew Smith were reported at $115. Among 32,838 Dentist profiles paid that year, the median was $70 and the middle half received between $27 and $192.
Show as a table
| Year | Andrew Smith | Dentist median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $214 | $62 | $24–$164 | $163 |
| 2020 | $90 | $73 | $24–$150 | $114 |
| 2021 | $310 | $72 | $24–$186 | $132 |
| 2022 | $0 | $73 | $26–$196 | $149 |
| 2023 | $620 | $75 | $28–$200 | $160 |
| 2024 | $0 | $73 | $27–$186 | $164 |
| 2025 | $115 | $70 | $27–$192 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 4 drugsPart D claims
106
Drug cost
$573
Branded share of claims
17.9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Penicillin V Potassium | Generic | 41 | $329 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 19 | $123 | |
| Chlorhexidine Gluconate | Generic | 13 | $64 | |
| Amoxicillin | Generic | 33 | $58 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 110,731 Part D prescribers listed as Dentist; they describe a distribution and say nothing about conduct.
Records
18 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Dentist in Utah
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.